A Pre-Operative Window Study Evaluating Denosumab, a RANKligand (RANKL) Inhibitor and Its Biological Effects in Young Premenopausal Women Diagnosed With Early Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2018
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Early breast cancer
- Focus Pharmacodynamics
- Acronyms D-Beyond
- 31 Aug 2018 Biomarkers information updated
- 01 Sep 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 01 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.